echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Preventive drug treatment for migraines

    Preventive drug treatment for migraines

    • Last Update: 2020-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Headacheise is a common symptom and an important reason for patients to visit a doctorMigraines are a recurrent side-side headache disorder with an estimated 16 per cent prevalence, which is more common in women (3:1.1 for men and women), and can be divided into acute, burstand and chronic migraines, depending on the number of seizures and oftenMigraines have the following characteristics: 4 to 72 hours of pain on one side, throbbing, moderate to severe intensity, aggravated by physical activity, accompanied by nausea, vomiting, sound fear or light fear, some patients may have reversible pre-eclampsia before the onset of headache, including visual abnormalities, one-sided sensory abnormalities, speech function, etcPreventive medication can reduce the frequency, severity, and prevent progression into chronic migraines, which can help improve the quality of life of patients
    First-line drugs (evidence confirms effective) second-line drugs (evidence suggests may be effective) sodium divalatin venrafasin to beasterin flufaloquatin naratricemmetolol zomiquatin pnodolol atrol sadol artrolol sadol nadorol yn yflon 2012 American Neurology Association and American Headache Association guidelines recommended to prevent the prevention of migraine Suggested to be effective drugs - beta blockers Nebilol, bisomolol, pindorol anticonvulin and anti-epileptic drugs carbamazepine, gabapentin antidepressants donot, demethylin, protitron, fluoxetine calcium channel receptor blockers nikatil, Verapami, nemodipine non-steroidal anti-inflammatory drug epsinACEI/ARB Candisatan, Rinopuri Calconite Gene-Related Peptide (CGRP) monoclonal antibody erenumab, galcanezumab, fremanezumab first-line and second-line drugs for the prevention of migraines First-line and second-line drugs Start-up Daily Dose Adverse Reactions Contraindication beta blocker Puplinor 50mg bid 120 to 240mg biq/tid Low blood pressure, impotence, drowsiness asthma heart rate through COPD metorol 50mg 37.5 to 200mg?? 50 to 500mg bid hair loss, fatigue, dizziness, liver failure, nausea (common), pancreatitis, drowsiness, platelet reduction, tremors, weight gain liver dysfunction, pregnancy (with neurotube malformations may be) sodium dilated acid 500mg 500 to 1000mg topropyl esters 15 to 25 mg 25 to 200mg Abnormal sensations (common), loss of appetite, memory and attention disorders, fatigue, kidney stones, language disorders, metabolic acidosis, nausea pregnancy (with cleft lip risk), closed-angle glaucoma, liver dysfunction antidepressants Venrafasin 10mg 25 to 150mg mouth dry, hypertension, insomnia, pupil enlargement, nausea, tension, epilepsy and monoamine oxidase inhibitors, Acute myocardial infarction, severe hypertension, epilepsy Amitillin 37.5mg 150mg blurred vision, constipation, lower epilepsy threshold, dry mouth, erect hypotension, QT extension, sedation, tachycardia, urinary retention Monoamine oxidase inhibitors are used in combination, prostate hyperplasia, epilepsy, glaucoma and other drugs, psiphytic 500 to 1100 mg of the gastrointestinal mild and temporary discomfortSymptoms of nausea, vomiting, indigestion and constipation To those who have asthma, rhinitis and rhin-polyps syndrome caused by aspirin or other nonsteroidal anti-inflammatory drugs; Itchy, paralysis, nosebleeds, burning sensations, tingling without coenzyme Q 10 300mg appetite loss, nausea, stomach discomfort, diarrhea, etcpregnancy, lactation, liver and kidney impairment in addition to the drugs in the table, U.Sguidelines also recommend the use of small white chrysanthemum (50-300 mg bid), bee bee vegetables (50-75 mg bid) and other plant extractsMedication spent in special populations in children only fluoroguire (selective calcium ion antagonist) has sufficient evidence to prevent effective migraine in children;Menstrual quatcoan classes, including fluophynasine, naraquatin and zomiquatin, have been shown to be effective, with the most significant evidence of fluophynasine to prevent menstrual migraines; estrogen-preventing menstrual migraines may be effectivePregnancy Guidelines recommend giving priority to prevention of pregnancy-related migraines through non-drug interventions such as relaxation training, thermal biofeedback, cognitive behavioral therapy, acupuncture, etc., and the use of teratogenic drugs such as valproate, tothestine, ACEI, etc., with the option of beta receptor blockers if drug treatment is usedChronic Migraine Chronic Migraine Drug Prevention Is most well-documented for toritine and botulinum toxin A;
    Compared with the U.Sguidelines, the 2011 China Guidelines for The Diagnosis and Treatment of Migraines also includes fluoroquine, metformin and other preventive drugsAuthor: Blue Whale Xiaohu Source: Medical Voice
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.